Mon, Oct 20, 2014, 7:14 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Allergan Inc. Message Board

ARMed_with_fire_and_ice 34 posts  |  Last Activity: Oct 18, 2014 7:40 AM Member since: Dec 17, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 18, 2014 7:40 AM Flag

    Buy on the dips and you will be very happy!

  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 17, 2014 11:29 AM Flag

    Cytosorbents will be presenting at the Drexel Hamilton Microcap Conference sposnored by AMP LLL November 13th

  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 16, 2014 8:55 AM Flag

    Not good:

    http://www.thedailybeast.com/articles/2014/10/15/europe-s-problematic-ebola-patients.html#

  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 15, 2014 4:08 PM Flag

    The key growth driver for CytoSorbents is the US market, the report noted, with the company working to strengthen its resources by installing a cardiac surgery advisory board as well as recruiting a clinical management team to conduct a pivotal clinical trial. The analyst belives the company could be in a position to finalize the trial design and file an investigational drug exemption by the end of this year, in line with previous guidance.

    H.C. Wainwright also highlighted the company's HemoDefend blood purification product, which functions by prolonging the life of old blood cells while keeping new blood fresh. The product has potential applications in transfusions, with results from a phase 3 trial expected later this month at the American Association of Blood Banks conference.

    Partnership discussions are anticipated in the near future if positive results are yielded, wrote Ramakanth. "While our current model does not account for revenues from this product we view this as a potential upside," the analyst said.

    The company has also simplified its capitalization structure, and is in the process of completing requirements to up list to an "as yet undisclosed" national exchange, which H.C. Wainwright believes can be completed by the end of 2014.

    CytoSorbents' technology is based on biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances, such as drugs, dangerous chemicals, toxins, cytokines, free hemoglobin, and antibodies, from blood and other bodily fluids.

  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 15, 2014 4:07 PM Flag

    Already provided, but here is full report:

    In the analyst report, the firm cited strong revenue growth, with CytoSorbents announcing preliminary third quarter sales yesterday of nearly $1 million, an increase of 50 percent compared to the second quarter of 2014 and more than 390 percent versus the same period last year. CytoSorbents (OTCBB:CTSO) rose on Wednesday after the critical care-focused company beat expectations with its preliminary third quarter results and had its buy rating reiterated by analysts at H.C. Wainwright, who said multiple growth drivers still remain.
    Analyst Swayampakula Ramakanth reiterated his buy rating and 12-month price target of $1.00, on the continued belief the shares are undervalued. The company, which uses blood purification products to treat life threatening diseases, added 6.6 percent today to 27.4 cents.
    In the analyst report, the firm cited strong revenue growth, with CytoSorbents announcing preliminary third quarter sales yesterday of nearly $1 million, an increase of 50 percent compared to the second quarter of 2014 and more than 390 percent versus the same period last year.
    Based on the latest announcement, H.C. Wainwright expects sales to reach over $3 million for fiscal year 2014, better than its previous estimate of $2.56 million.
    The analyst wrote that repeat orders from current customers and existing distributors were drivers for sales in the latest period, which H.C. Wainwright believes could continue into the fourth quarter and beyond based on continued growth in current markets and a potential launch in the Middle East.
    Future sales are also expected to increase based on an increased sales force in Germany from 4 to 10 by year-end, and market expansion of certain distributors. H.C. Wainwright is projecting total revenues of nearly $8.15 million in fiscal year 2015.

  • Reply to

    Still Looking

    by payingattention2 Sep 25, 2014 10:34 AM
    armed_with_fire_and_ice armed_with_fire_and_ice Oct 15, 2014 2:31 PM Flag

    Debacle!

  • armed_with_fire_and_ice armed_with_fire_and_ice Oct 14, 2014 4:14 PM Flag

    Got price right but only half the volume. Oh well. Let's see what happens!

  • Reply to

    U.S. ARMY

    by slappe_was Oct 14, 2014 10:17 AM
    armed_with_fire_and_ice armed_with_fire_and_ice Oct 14, 2014 1:23 PM Flag

    More on Tweet: Posted by Van Hipp: Chairman of the American Defense International, Inc. formerly Deputy Assistant Secretary of the US Army:

    His website is www.vanhipp.com

  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 14, 2014 9:52 AM Flag

    Getting Noticed!

  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 14, 2014 9:13 AM Flag

    This may be far fetched but we will see. Once people uncover this hidden play, as well as hidden ebola play, the volume will go crazy. My prediction:

    5M shares today: .$26 price
    10M shares tomorrow: $.33 price
    16M shares Friday: $.45 price

    May be wishful thinking but certainly not out of the question.

    I hope I am right.

  • Reply to

    Here we go!

    by jjgb072000 Oct 14, 2014 6:53 AM
    armed_with_fire_and_ice armed_with_fire_and_ice Oct 14, 2014 7:09 AM Flag

    For those now interested in buying ion the dips. NOW is the time. I see $.50 very soon!

    Chan touched on everything we needed. Go CTSO!!!

  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 12, 2014 6:34 PM Flag

    Could CytoSorb® Help?
    The 2014 Ebola epidemic in West Africa, called an “international emergency” by the WHO, continues to grow and has already infected nearly 1,900 people, and claimed more than 1,000 lives. Epidemic is expected to continue throughout the year. Our Strategy for outreach:
    • WHO
    • FDA
    • CDC
    • Government agencies such as USAMRIID (US Army Medical Research Institute of Infectious Diseases)
    • Non-profit organizations
    • Hospitals treating Ebola patients inside/outside of West Africa
    •Europe
    •U.S.

  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 12, 2014 6:32 PM Flag

    Seems to me CTSO should become more visible as a potential devise that could be used to prevent cytokine storm and allow immune system time to work.

    From Sepsis Alliance Website:

    Ebola Treatment

    There is no treatment for Ebola at this point. People who have Ebola often develop sepsis, so treatment involves trying to keep them from going into septic shock and managing organ dysfunction, such as kidney shut down, dropping blood pressure, difficulty breathing, etc. According to the National Institutes of Health (NIH), those who die from Ebola usually die from shock, low blood pressure.

  • armed_with_fire_and_ice by armed_with_fire_and_ice Oct 12, 2014 6:26 PM Flag

    For those that forgot:

    Ebola Virus
    • Ebola is one of the most deadly viruses known with a very high mortality rate of 50-90% depending upon the strain, and very contagious (bodily fluids)
    • Following an incubation phase of 2-21 days, has an abrupt onset of symptoms including high fever, chills, weakness and body pain, followed by more severe symptoms including diarrhea, cough, headache, and bleeding with vomiting of blood or blood in stool
    • Patients typically die with time to death (from onset of symptoms) of 6-16 days. Culminates in a cytokine release syndrome
    • Key to why Ebola is so deadly is its ability to evade the immune response, resulting in advanced infection that culminates in cytokine storm, deadly inflammation, and multiple organ failure
    •Initial suppression of the anti-viral cytokine immune response allows rampant viral replication
    •Release of soluble viral glycoproteins (sGP) that interfere with white blood cell activation and act as a decoy so that antibodies cannot neutralize the virus
    • CytoSorb may have benefit by reducing cytokine storm and sGP, buying time for the immune system to kill the virus

  • Reply to

    Still Looking

    by payingattention2 Sep 25, 2014 10:34 AM
    armed_with_fire_and_ice armed_with_fire_and_ice Sep 25, 2014 11:47 AM Flag

    Oversold at this point. Just bought 1600 more shares. Come on KBR, this is rediculous!

  • Reply to

    Only way I get margin call if this hits $ 18.00

    by boyshah15 Sep 4, 2014 5:58 PM
    armed_with_fire_and_ice armed_with_fire_and_ice Sep 4, 2014 7:22 PM Flag

    No way I short now. Long is Up from here. Gambled and went long on Tuesday. I did the same with SPLK and VEEV as well. The strategy has being great!

  • armed_with_fire_and_ice armed_with_fire_and_ice Sep 3, 2014 7:38 PM Flag

    Thanks, Sorry, did not see that. My bad.

  • armed_with_fire_and_ice by armed_with_fire_and_ice Sep 3, 2014 6:48 PM Flag

    Nothing new, but at least its publicity.

    Google Today's Medical Developments Cytosorb

    or

    wwwdotonlinetmddotcom

  • armed_with_fire_and_ice by armed_with_fire_and_ice Aug 28, 2014 6:32 PM Flag

    More Insider Selling. Not good

  • armed_with_fire_and_ice armed_with_fire_and_ice Aug 19, 2014 4:43 PM Flag

    PART 2:

    This looks to us like it will translate in to a steady, modest growth trajectory, with no impending near-term milestone.

    As for approval in the U.S., a small pilot trial is underway that is funded by the U.S. Air Force in trauma and rhabdomyolysis (muscle-crushing trauma). Although anecdotal results show that CytoSorb is saving lives in Europe, the company must do a trial in the U.S. before the FDA considers the product for approval. Importantly, the FDA has reviewed the safety date from the European trial and given CytoSorbents an investigational device exemption approval to conduct the Air Force trial. This application is one possible path to U.S. approval. The company also plans to commence a pivotal trial in sepsis, cardiac surgery or perhaps other indications by the end of this year that could lead to U.S. approval.

    I project an organic ramp-up in growth as CytoSorbents expands its sales force, which is small now because it's a small company, with a $72M market cap. It appears as though CytoSorbents will achieve $1M in trailing 12-month sales in this quarter, with sales mainly in just three countries—Germany, Austria and the United Kingdom.

AGN
179.25+1.76(+0.99%)Oct 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.